
Faculty, Staff and Student Publications
Publication Date
1-1-2025
Journal
CA: A Cancer Journal for Clinicians
Abstract
Poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors, such as olaparib, talazoparib, rucaparib, and niraparib, comprise a therapeutic class that targets PARP proteins involved in DNA repair. Cancer cells with homologous recombination repair defects, particularly BRCA alterations, display enhanced sensitivity to these agents because of synthetic lethality induced by PARP inhibitors. These agents have significantly improved survival outcomes across various malignancies, initially gaining regulatory approval in ovarian cancer and subsequently in breast, pancreatic, and prostate cancers in different indications. This review offers a comprehensive clinical overview of PARP inhibitor approvals, emphasizing their efficacy across different cancers based on landmark phase 3 clinical trials.
Keywords
Humans, Poly(ADP-ribose) Polymerase Inhibitors, Neoplasms, Female, Phthalazines, Male, Ovarian Neoplasms, Antineoplastic Agents, Piperazines, Breast Neoplasms, Clinical Trials, Phase III as Topic, Piperidines, Prostatic Neoplasms, Indoles, Indazoles, Pancreatic Neoplasms, breast cancer, ovarian cancer, pancreatic cancer, poly(adenosine diphosphate ribose) polymerase inhibitors, prostate cancer.
DOI
10.3322/caac.21870
PMID
39791278
PMCID
PMC11929130
PubMedCentral® Posted Date
1-10-2025
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Genetic Phenomena Commons, Medical Genetics Commons, Oncology Commons